Galectin Therapeutics (NASDAQ:GALT) Director Harold Shlevin Sells 22,268 Shares

Galectin Therapeutics Inc. (NASDAQ:GALT) Director Harold Shlevin sold 22,268 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.04, for a total transaction of $112,230.72. Following the transaction, the director owned 6,500 shares in the company, valued at approximately $32,760. This trade represents a 77.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Galectin Therapeutics Stock Down 6.6%

Shares of NASDAQ:GALT opened at $4.64 on Wednesday. Galectin Therapeutics Inc. has a 52 week low of $2.03 and a 52 week high of $7.13. The company has a 50-day moving average price of $2.65 and a 200 day moving average price of $3.06. The company has a market cap of $305.59 million, a P/E ratio of -11.32 and a beta of 0.47.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Analysts expect that Galectin Therapeutics Inc. will post -0.37 EPS for the current year.

Institutional Investors Weigh In On Galectin Therapeutics

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Galectin Therapeutics by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company’s stock worth $9,520,000 after acquiring an additional 63,419 shares during the period. Jane Street Group LLC purchased a new stake in Galectin Therapeutics during the second quarter worth $1,580,000. Marshall Wace LLP boosted its position in Galectin Therapeutics by 8.6% during the fourth quarter. Marshall Wace LLP now owns 602,134 shares of the company’s stock worth $2,505,000 after purchasing an additional 47,873 shares in the last quarter. Wealthspire Advisors LLC grew its holdings in Galectin Therapeutics by 25.5% in the fourth quarter. Wealthspire Advisors LLC now owns 601,973 shares of the company’s stock valued at $2,504,000 after purchasing an additional 122,455 shares during the last quarter. Finally, Commonwealth Equity Services LLC grew its holdings in Galectin Therapeutics by 13.3% in the fourth quarter. Commonwealth Equity Services LLC now owns 334,096 shares of the company’s stock valued at $1,390,000 after purchasing an additional 39,195 shares during the last quarter. Hedge funds and other institutional investors own 11.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on GALT shares. Weiss Ratings upgraded Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 18th. Wall Street Zen raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a research note on Tuesday, June 23rd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $11.00.

Galectin Therapeutics Company Profile

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.